Systemic sclerosis & Raynaud's
Development of an enzyme-linked immunosorbent assay for the efficient detection of autoantibodies against nuclear valosin-containing protein-like protein (NVL) 2 using its manipulated cDNA
Authors' conclusion
We found more anti-NVL2 antibody-positive cases than any previous study, as far as we know.
Study context
- Population
- Sera from patients with various conditions, examined by an anti-mNVL2 ELISApatients' sera included
- Participants
- 1,676 participants
- Comparison
- Anti-nucleolar antibody (ANoA)-positive vs ANoA-negative vs Healthy control
- ANoA-positiven = 167
- ANoA-negativen = 120
- Healthy controln = 17reference
- Outcome
- Anti-mNVL2 ELISA positivity
Methodological detailsELISA using recombinant modified NVL2 (mNVL2), confirmation by immunoprecipitation-Western blotting
- ELISA using recombinant modified NVL2 (mNVL2)
- Confirmation by immunoprecipitation-Western blotting
Performance
As reported in the abstract
ANoA-positive
18
events
ANoA-negative
1
events
- ANoA-negative serum judged false positive
- 1
- Anti-NVL2 antibodies in homogeneous nucleolar (AC-8) indirect immunofluorescence (IIF) patterns
- 17.0%
Further findings
| Outcome | P value |
|---|---|
| Anti-mNVL2 ELISA titres, anti-NVL2-positive SSc vs non-SScTitres significantly higher in SSc | P < 0.042 |
Anti-NVL2 antibody-positive patients by diagnosis
- Systemic sclerosis (SSc)
- 6
- Idiopathic interstitial pneumonia
- 5
- Other diseases
- 7
Original publication
Development of an enzyme-linked immunosorbent assay for the efficient detection of autoantibodies against nuclear valosin-containing protein-like protein (NVL) 2 using its manipulated cDNA. RMD Open. Published 7 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →